News | July 08, 2008

Cryoablation Just as Effective as Radiofrequency in Treating Atrial Flutter

July 9, 2008 - New research shows catheter cryoablation is comparably effective to radiofrequency catheter ablation for the treatment of atrial flutter (AFL) and may have some safety advantages over the use of radiofrequency.

The findings are detailed in a study published in the July edition of the HeartRhythm Journal, the journal of the Heart Rhythm Society. This is the first large, multi-center study to prove the acute and long-term safety and efficacy of catheter based-cryoablation for the treatment of AFL, reporting six-month follow-up results for 160 patients.

AFL is characterized by a rapid heartbeat and is caused by a single electrical wave that circulates very rapidly in the atrium, about 300 times a minute, leading to a very fast, steady heartbeat. This rapid heartbeat disrupts the pumping of blood to the heart and complications of atrial flutter can potentially lead to a stroke.

Currently, radiofrequency catheter ablation is a very common and effective treatment of AFL, with cure rates around 95 percent. However, radiofrequency catheter ablation can cause serious side effects, such as coagulum formation or endocardial charring which can lead to potential long-term health complications. Catheter-based cryoablation is said to be a viable and safer alternative to radiofrequency catheter ablation, but its efficiency in treating AFL had not been systematically evaluated in a large clinical trial until now.

The study led by Gregory K. Feld, M.D., of the University of California, San Diego (UCSD) School of Medicine, performed catheter-based cryoablation at 12 medical centers in 160 patients with cavotricuspid isthmus-dependent AFL. Patients were evaluated at one, three and six months and underwent weekly and symptomatic event monitoring. The study revealed 90.2 percent of patients remained clinically free of AFL, proving the effectiveness of cryoablation in the treatment of AFL.

“A study of this size, performed at multiple centers, better validates the safety and efficacy of a device for arrhythmia treatment, compared to smaller, single center studies,” Feld said. “The validity of this large multi-center study proves that cryoablation is reliable treatment of atrial flutter, and is further supported by the many safety advantages cryoablation offers over radiofrequency treatment.”

As shown in this study and others, in addition to the newly proven effectiveness of cryoablation in the treatment of AFL, cryoablation also presents a number of safety advantages over radiofrequency, including: less pain, less risk of coagulum formation, less risk of causing heart block and no risk of causing pulmonary vein stenosis which is the narrowing of the vein caused by heating.

For more information: www.heartrhythmjournal.com


Related Content

News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
News

May 4, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias ...

Home May 04, 2022
Home
News

April 5, 2021 — Acutus Medical today announced initial U.S. enrollments in the company’s AcQForce Flutter ...

Home April 05, 2021
Home
News

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ...

Home June 16, 2020
Home
News

May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SERF) ...

Home May 08, 2020
Home
Subscribe Now